Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib
Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib is a scholarly work, published in 2019 in ''Clinical Lymphoma, Myeloma & Leukemia''. The main subjects of the publication include crizotinib, biology, Large cell, anaplastic large-cell lymphoma, ALK, cancer research, lymphoma, TNF receptor superfamily member 8, chronic lymphocytic leukemia, Erb-b2 receptor tyrosine kinase 2, chromosomal translocation, alectinib, receptor tyrosine kinase, -, and ALK inhibitor. ALK overexpression results from a balanced translocation between chromosome 2 (ALK) and chromosome 5 (NPM), resulting in both the overexpression and the constitutive activation of the kinase domain of ALK.